Quality Prescribing Guidance for Cardiovascular Risk Reduction 2026-2029
Pharmacotherapies for obesity
We recommend that clinicians:
- Ask for permission each time before discussing overweight, obesity or central adiposity and before taking measurements
- In adults with Body Mass Index (BMI) below 35 kg/m2, measure and use their waist-to-height ratio, as well as their BMI, as a practical estimate of central adiposity and use these measurements to help to assess and predict health risks (for example, type 2 diabetes, hypertension or cardiovascular disease)
- Incretin-based therapies should be considered for those who meet Scottish Medicines Consortium (SMC)/consensus statement criteria